Grandchamp was speaking at Sanofi's global virtual media watch party at the 81st Scientific Sessions of the American Diabetes Association. “Diabetes is a top priority for Sanofi and as a global leader in this space, people living with diabetes are at the heart of all we do. We know this requires us to go beyond medicine. This is why Sanofi is dedicated to developing new innovations, combining medicines and technologies, generating clinical evidence, and providing patient support and education programmes that allow for a more holistic approach to the management of diabetes.”
Ahead of sharing the results of the SoliMix trial, Grandchamp said that not only was Sanofi one of the first companies in the world to produce insulin, “We continue to be at the forefront of diabetes management, creating breakthrough advances that have helped to set the standards of treatment.”
The first randomised head-to-head clinical trial comparing the safety and efficacy of iGlarLixi (Soliqua) versus premix insulin in adults with insufficiently controlled type 2 diabetes on basal insulin plus one or two oral antidiabetic agents, the SoliMix trial found that when managing type 2 diabetes, the once-daily iGlarLixi (Soliqua) edged out the twice-daily premix insulin analogue BIAsp 30.
“The key results of the SoliMix study are that in comparison with the fixed mixture, BIAsp 30, the fixed-ratio combination iGlarLixi demonstrated non-inferiority and, in fact, superiority in terms of HbA1c reduction,” said Prof Rory McCrimmon (lead clinician for the Scottish Diabetes Research Network). “Now, importantly, it did so without causing significant body weight change – this was increased with the BIAsp 30 but reduced with iGlarLixi. This is something clearly very important to many of our patients with type 2 diabetes who have significant weight. The number of patients who achieved the HbA1c target without weight gain and without significant hypoglycaemia was increased with the iGlarLixi.
“Important for the physician,” said Prof McCrimmon, “the adverse effect profile was very much as we might expect from the GLP-1 receptor agonist. And importantly, serious adverse events were rare and study discontinuations related to adverse events were very low.”
LOOKING TO THE FUTURE
“There is much work still to be done,” said Prof Silvestri. “Almost half of the people living with diabetes are not at glycaemic target.
“Our use of real-life data and analytics help improve understanding and underpins our solutions targeted to meet individual daily needs. Our approach will bring together our broad insulin-based portfolio with the power of digital and personal technology. Developing a comprehensive care ecosystem, we hope to help individuals living with diabetes achieve better outcomes and support long-lasting, healthy habits. By championing individual solutions that will help set a new standard of care, we hope to empower people to manage their own health simply and conveniently and live the life they want, every day, anywhere, undeterred by diabetes."